Jefferies Group Weighs in on Pfizer Inc.’s FY2017 Earnings (PFE)
Pfizer Inc. (NYSE:PFE) – Jefferies Group decreased their FY2017 earnings per share estimates for Pfizer in a report released on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings per share of $2.67 for the year, down from their prior estimate of $2.71. Jefferies Group currently has a “Hold” rating and a $36.00 target price on the stock. Jefferies Group also issued estimates for Pfizer’s FY2018 earnings at $2.92 EPS, FY2019 earnings at $2.87 EPS and FY2020 earnings at $3.08 EPS.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $0.56 earnings per share.
PFE has been the topic of several other reports. Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 22nd. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 price target on shares of Pfizer in a report on Monday, August 22nd. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price target on the stock. in a report on Thursday. Finally, Argus restated a “buy” rating and set a $39.00 price target on shares of Pfizer in a report on Tuesday, October 4th. Eleven research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $38.59.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/jefferies-group-weighs-in-on-pfizer-inc-s-fy2017-earnings-pfe.html
Pfizer (NYSE:PFE) opened at 32.66 on Monday. The company has a market capitalization of $198.10 billion, a PE ratio of 28.95 and a beta of 0.86. Pfizer has a 52 week low of $28.25 and a 52 week high of $37.39. The company has a 50-day moving average of $34.02 and a 200-day moving average of $34.27.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.
Several institutional investors have recently added to or reduced their stakes in the stock. Narwhal Capital Management raised its position in Pfizer by 1.4% in the first quarter. Narwhal Capital Management now owns 125,322 shares of the biopharmaceutical company’s stock valued at $3,715,000 after buying an additional 1,700 shares in the last quarter. Boston Advisors LLC raised its position in Pfizer by 0.4% in the first quarter. Boston Advisors LLC now owns 619,828 shares of the biopharmaceutical company’s stock valued at $18,372,000 after buying an additional 2,606 shares in the last quarter. Regent Investment Management LLC raised its position in Pfizer by 77.8% in the first quarter. Regent Investment Management LLC now owns 33,768 shares of the biopharmaceutical company’s stock valued at $1,001,000 after buying an additional 14,781 shares in the last quarter. Carroll Financial Associates Inc. raised its position in Pfizer by 3.2% in the first quarter. Carroll Financial Associates Inc. now owns 123,836 shares of the biopharmaceutical company’s stock valued at $3,670,000 after buying an additional 3,873 shares in the last quarter. Finally, City Holding Co. raised its position in Pfizer by 5.5% in the first quarter. City Holding Co. now owns 49,450 shares of the biopharmaceutical company’s stock valued at $1,465,000 after buying an additional 2,575 shares in the last quarter. 69.66% of the stock is currently owned by institutional investors.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.